Avance Biosciences

Founded in 2009, Avance Biosciences is a specialized CRO/CTO offering critical analytical and bioanalytical testing services under stringent regulatory standards (CGMP/GLP). Its core business model is providing outsourced services to support drug development from preclinical stages through commercialization, focusing on advanced modalities like cell and gene therapy. The company serves over 300 clients globally, positioning itself as a trusted partner in the complex biopharmaceutical development landscape. Its value proposition lies in integrating cutting-edge scientific technologies with rigorous quality management systems.

Integrated suite of CGMP/GLP-compliant analytical technologies including Next-Gen Sequencing, PCR, immunoassays (ELISA, MSD), flow cytometry, microbiology, and analytical chemistry to support drug development and testing.

Competes in the fragmented CRO/CTO market against large, full-service global CROs (e.g., LabCorp, IQVIA), specialized analytical service providers, and the internal capabilities of large pharmaceutical companies. Differentiation is based on technical expertise in advanced modalities, regulatory quality, and client service.